Radiopharmacies Market Report 2026

The radiopharmacies market size has grown strongly in recent years. It will grow from $10.3 billion in 2025 to $11.12 billion in 2026 at a compound annual growth rate (CAGR) of 8%. The growth in the historic period can be attributed to growing prevalence of cancer and chronic diseases, rising adoption of nuclear medicine imaging procedures, increasing demand for accurate diagnostic radiopharmaceuticals, expansion of hospital-based nuclear medicine departments, growing regulatory focus on safe radioactive material handling.

The radiopharmacies market size is expected to see strong growth in the next few years. It will grow to $15.26 billion by 2030 at a compound annual growth rate (CAGR) of 8.2%. The growth in the forecast period can be attributed to increasing development of targeted radionuclide therapies, rising investment in PET and SPECT imaging technologies, growing expansion of personalized medicine applications, increasing establishment of centralized radiopharmacy networks, rising demand for advanced radiopharmaceutical logistics and cold chain solutions. Major trends in the forecast period include increasing demand for targeted radiopharmaceutical therapies in oncology, growing adoption of centralized radiopharmacy services for efficient dose preparation, rising focus on radiation safety and regulatory compliance in radiopharmacies, expansion of nuclear medicine applications in cardiology and neurology, increasing investment in advanced quality control and assurance systems for radiopharmaceutical handling.

The increasing prevalence of cancer and chronic diseases is expected to propel the growth of the radiopharmacies market going forward. Cancer and chronic diseases refer to long lasting health conditions, such as cancer, diabetes, heart disease, and respiratory illnesses, that require ongoing medical attention and can persist for months or years. The prevalence of cancer and chronic diseases is increasing due to aging populations because as people grow older, their risk of developing long-term illnesses such as cancer, diabetes, and heart disease naturally increases. Radiopharmacies support the diagnosis and treatment of cancer and chronic diseases by producing and supplying specialized radioactive drugs utilized in medical imaging and targeted therapies, enabling precise detection, monitoring, and therapy of these conditions. For instance, in February 2024, according to the World Health Organization, over 35 million new cancer cases are predicted in 2050, a 77% increase from the estimated 20 million cases in 2022. Therefore, the increasing prevalence of cancer and chronic diseases is driving the growth of the radiopharmacies market.

Leading companies operating in the radiopharmacies market are concentrating on developing innovative initiatives such as advanced radiopharmaceutical production facilities to enhance production efficiency and ensure a reliable supply of diagnostic and therapeutic radiopharmaceuticals. Advanced radiopharmaceutical production facilities are specialized centres that manufacture radioactive compounds for medical imaging and therapy with high precision and safety, helping ensure consistent quality, faster production, and reliable supply of diagnostic and therapeutic radiopharmaceuticals. For instance, in October 2024, PharmaLogic Holdings Corp. opened a state-of-the-art radiopharmaceutical production facility in Los Angeles to enhance its capacity to supply critical imaging agents. The facility features automated synthesis modules, stringent quality control protocols, and scalable production lines, enabling consistent and high-purity radiotracer manufacturing. It supports the production of PET and SPECT imaging agents, reducing human error, minimizing contamination risks, and improving turnaround times compared to conventional laboratories.

In January 2025, Telix Pharmaceuticals Limited acquired RLS (USA) Inc. for an undisclosed amount. Through this acquisition, Telix aims to establish an integrated radiopharmaceutical ecosystem, enhancing its capability to deliver novel therapeutic and diagnostic radiopharmaceuticals across the U. S., streamline its supply chain, accelerate clinical development programs, and expand patient access to innovative imaging and treatment solutions. RLS (USA) Inc. is a U. S. -based healthcare technology company specializing in radiopharmacies.

Major companies operating in the radiopharmacies market are Cardinal Health Inc., Siemens Healthineers AG, GE HealthCare Technologies Inc., BWX Technologies Inc., Bracco Imaging S. p. A., Lantheus Holdings Inc., China Isotope & Radiation Corporation, Ion Beam Applications S. A. (IBA), Telix Pharmaceuticals Limited, Eckert & Ziegler Strahlen, PharmaLogic Holdings Corp., Shine Technologies LLC, NTP Radioisotopes SOC Ltd., NorthStar Medical Radioisotopes LLC, ITM Isotope Technologies Munich SE, ARTBIO Inc., Isotopia Molecular Imaging Ltd., AdvanCell Isotopes Pty Ltd, Futurechem Co. Ltd., Jubilant Radiopharma Pvt. Ltd., Cyclotek (Aust) Pty Ltd., Radiomedix Inc., Iso‑Tex Diagnostics Inc., Nucleus RadioPharma Inc.

North America was the largest region in the radiopharmacies market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the radiopharmacies market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the radiopharmacies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The radiopharmacies market consists of revenues earned by entities by providing services such as preparation and compounding of radiopharmaceuticals, quality control testing, packaging and labeling of radioactive drugs, distribution to healthcare facilities, and regulatory compliance management. The market value includes the value of related goods sold by the service provider or included within the service offering. The radiopharmacies market also includes sales of radiotracers, radioisotopes, cold kits, radiolabeled monoclonal antibodies, and quality control reagents and testing kits. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.